[NON-CARDIAL EFFECTS OF SGLT2 INHIBITORS (REVIEW)].
The article reveals the efficacy and safety aspects of a new class of antidiabetic drugs - SGLT2 inhibitors. The results of clinical and experimental studies of the principle of renal glucose reabsorption inhibition usage in the treatment of type 2 diabetes are presented in the article. Drugs of this class offer a new, non-insulin-dependent mechanism of action, lack of negative effect on body weight, favorable pharmacokinetic properties and good tolerance. However, data, requiring further more detailed analysis, were found, namely: a glucosuria as a risk factor for genitourinary system infections, increased levels of blood creatinine, increased urinary calcium excretion, ketogenesis. Also nephrogenic and cancer effects need more detailed analysis according to the ratio of risk/benefit.